Cytoplasmic glycoengineering enables biosynthesis of nanoscale glycoprotein assemblies
Established bacterial glycoengineering platforms limit access to protein and glycan substrates. Here the authors design a cytoplasmic protein glycosylation system, Glycoli, to generate a variety of multivalent glycostructures.
Guardado en:
Autores principales: | Hanne L. P. Tytgat, Chia-wei Lin, Mikail D. Levasseur, Markus B. Tomek, Christoph Rutschmann, Jacqueline Mock, Nora Liebscher, Naohiro Terasaka, Yusuke Azuma, Michael Wetter, Martin F. Bachmann, Donald Hilvert, Markus Aebi, Timothy G. Keys |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ac3f91e741e14ae68b947f045f6333f3 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Direct quality control of glycoengineered erythropoietin variants
por: Tomislav Čaval, et al.
Publicado: (2018) -
A platform for glycoengineering a polyvalent pneumococcal bioconjugate vaccine using E. coli as a host
por: Christian M. Harding, et al.
Publicado: (2019) -
Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist
por: Cassandra L. Pegg, et al.
Publicado: (2017) -
Modulation of Epstein-Barr Virus Glycoprotein B (gB) Fusion Activity by the gB Cytoplasmic Tail Domain
por: Nicholas J. Garcia, et al.
Publicado: (2013) -
De novo peptide grafting to a self-assembling nanocapsule yields a hepatocyte growth factor receptor agonist
por: Yamato Komatsu, et al.
Publicado: (2021)